EGFR antibody (pTyr1173) (Alexa Fluor 647)

Catalog No. ABIN1177051

Product Details anti-EGFR Antibody (Alexa Fluor 647)

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Binding Specificity: pTyr1173

Reactivity: Human, Mouse, Rat, Dog

Host: Mouse

Clonality: Monoclonal

Conjugate: This EGFR antibody is conjugated to Alexa Fluor 647

Application: Intracellular Staining (ICS)

Brand: BD Phosflow™

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Phosphorylated Human EGF Receptor Peptide

Clone: 9H2

Isotype: IgG1 kappa

Application Details

Sample Volume: 20 μL

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Aqueous buffered solution containing BSA and ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The antibody was conjugated to Alexa Fluor® 647 under optimum conditions, and unreacted Alexa Fluor® 647 was removed.

References for anti-EGFR antibody (Alexa Fluor 647) (ABIN1177051)

Olayioye, Neve, Lane, Hynes: "The ErbB signaling network: receptor heterodimerization in development and cancer." in: The EMBO journal, Vol. 19, Issue 13, pp. 3159-67, (2000) (PubMed).

Target Details for EGFR

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Alternative Name: EGF Receptor (EGFR Products)

Background: Epidermal Growth Factor (EGF) elicits a variety of cellular responses that are initiated by EGF Receptor (EGFR) binding and activation of intrinsic tyrosine kinase activity. EGFR, also known as ErbB1 or HER1, is a member of the ErbB class of receptor protein tyrosine kinases. It has an extracellular ligand-binding domain, a single transmembrane region, and a cytoplasmic region containing a protein tyrosine kinase domain and a c-terminal regulatory domain with many phosphorylation sites. Following ligand binding, EGFR forms homodimers and heterodimers with ErbB2. Specific C-terminal tyrosine residues are then autophosphorylated and, in turn, bind to adaptor proteins, kinases, or protein tyrosine phosphatases. Specifically, phosphorylated tyrosine 1173 (Y1173) interacts with Shc, SHP1, and PLCg, which mediate downstream signaling cascades and negative feedback regulation of EGFR activation. Inappropriate expression or mutations of EGFR and/or deregulation of its signaling pathways are associated with many types of cancer, making EGFR a promising target for cancer therapies. The 9H2 monoclonal antibody recognizes the phosphorylated Y1173 in the regulatory domain of human EGFR.

Pathways: NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins